You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Institute of Cancer Research embraces olaparib recommendation

The Institute of Cancer Research (ICR) has welcomed the ‘life-changing’ decision by the National Institute for Health and Care Excellence (NICE) to recommend AstraZeneca’s olaparib.